UAE

The primary national regulatory authority for health products in the UAE is the Ministry of Health and Prevention (MOHAP), which oversees the registration and market authorization of pharmaceuticals, medical devices, diagnostics, and digital health solutions at the federal level. The legal framework is anchored in Federal Law No. 4 of 1983 concerning the Pharmaceutical Profession and Institutions, as amended, alongside Cabinet and Ministerial Decisions that govern product classification, registration, post-market surveillance, and enforcement. Emirate-level authorities, specifically the Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DoH), maintain parallel registration and licensing requirements within their respective jurisdictions, meaning that companies may need to secure approvals from multiple bodies depending on their target markets. The general approval process involves product classification, submission of a registration dossier, technical review, inspection where applicable, and issuance of a registration certificate before any product may be legally marketed or supplied.

Key submission requirements include the appointment of a locally registered marketing authorization holder or licensed agent, as foreign manufacturers must be represented by a UAE-licensed entity throughout the regulatory process. MOHAP and the emirate-level authorities accept dossiers prepared in Common Technical Document (CTD) format in line with ICH guidelines for pharmaceuticals, and follow ISO and IMDRF standards for medical devices, including recognition of CE marking and US FDA clearance as supportive evidence for certain device categories. Digital health products and Software as a Medical Device (SaMD) are increasingly subject to dedicated guidance frameworks issued by DHA and DoH. Notable recent reforms include the UAE's active participation in the Gulf Cooperation Council (GCC) harmonization initiative under the Gulf Central Committee for Drug Registration (GCC-DR), the mandatory adoption of the Tatmeen track-and-trace serialization system for pharmaceuticals, and accelerated pathways introduced for innovative and priority health products aligned with the UAE's broader national health strategy and Vision 2031 objectives.

Public procurement of health products in the UAE operates across both federal and emirate levels, reflecting the country's federated governance structure. At the federal level, MOHAP coordinates procurement for federal health facilities and contributes to national stockpiling and essential medicines programs, while the Central Tenders Committee under the Ministry of Finance governs federal public tendering processes in accordance with Federal Decree-Law No. 6 of 2008 on public procurement. At the emirate level, Health authorities such as the DoH in Abu Dhabi and the DHA in Dubai manage procurement for their respective public hospital networks and primary care systems, often through dedicated procurement departments and long-term supply framework agreements. The Abu Dhabi Health Services Company (SEHA) is a key institutional buyer for the Abu Dhabi emirate, procuring across its extensive network of hospitals and clinics. Tenders are typically published through official government portals, and suppliers must hold valid product registrations, local trade licenses, and meet quality assurance documentation requirements to qualify for public sector contracts.

The UAE does not rely significantly on multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, given its high-income country status and self-funded public health system. However, UAE entities and government health initiatives may occasionally engage with international organizations in the context of humanitarian aid, regional health programs, or research collaborations. The private healthcare sector represents a substantial and growing share of health product demand, served through distributor networks, group purchasing arrangements by large private hospital groups such as Mediclinic and Cleveland Clinic Abu Dhabi, and direct supplier agreements. The UAE has introduced local manufacturing preference policies as part of its industrial strategy, including incentives under the Operation 300bn national industrial strategy and the Make in the Emirates initiative, which aim to attract pharmaceutical and medical device manufacturing investment and may confer advantages to locally produced or locally assembled products in public procurement evaluations.